$EMMA
Emmaus Life Sciences, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023042300 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $5.018M $10.76M
YoY Change 1.6% 150.97%
Cost Of Revenue $214.0K $508.0K
YoY Change -60.37% 28.28%
Gross Profit $4.804M $10.25M
YoY Change 9.21% 163.45%
Gross Profit Margin 95.74% 95.28%
Selling, General & Admin $4.366M $6.605M
YoY Change -5.64% 31.23%
% of Gross Profit 90.88% 64.43%
Research & Development $414.0K $320.0K
YoY Change -4.17% 7.38%
% of Gross Profit 8.62% 3.12%
Depreciation & Amortization $7.000K $9.000K
YoY Change -22.22% -10.0%
% of Gross Profit 0.15% 0.09%
Operating Expenses $4.780M $6.925M
YoY Change -5.51% 29.9%
Operating Profit $24.00K $3.326M
YoY Change -103.64% -330.97%
Interest Expense $1.909M $1.793M
YoY Change 25.59% 39.32%
% of Operating Profit 7954.17% 53.91%
Other Income/Expense, Net $180.0K $173.0K
YoY Change 2.86% 30.08%
Pretax Income $105.0K -$1.516M
YoY Change -124.65% -82.59%
Income Tax $38.00K -$34.00K
% Of Pretax Income 36.19%
Net Earnings $67.00K -$1.482M
YoY Change -117.14% -83.33%
Net Earnings / Revenue 1.34% -13.77%
Basic Earnings Per Share $0.00 -$0.03
Diluted Earnings Per Share -$0.01 -$0.03
COMMON SHARES
Basic Shares Outstanding 53.64M 53.64M
Diluted Shares Outstanding 138.4M 52.87M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.510M $1.361M
YoY Change 28.07% 38.59%
Cash & Equivalents $1.505M $1.361M
Short-Term Investments
Other Short-Term Assets $647.0K $434.0K
YoY Change 26.61% 2.84%
Inventory $1.650M $1.814M
Prepaid Expenses $736.0K $337.0K
Receivables $4.587M $5.573M
Other Receivables $0.00 $0.00
Total Short-Term Assets $9.257M $9.847M
YoY Change 45.05% 49.51%
LONG-TERM ASSETS
Property, Plant & Equipment $60.00K $68.00K
YoY Change -24.05% -20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $17.74M $18.30M
YoY Change 6.89% 7.77%
Other Assets $293.0K $276.0K
YoY Change 13.13% 5.75%
Total Long-Term Assets $38.20M $40.44M
YoY Change 6.64% 2.63%
TOTAL ASSETS
Total Short-Term Assets $9.257M $9.847M
Total Long-Term Assets $38.20M $40.44M
Total Assets $47.45M $50.29M
YoY Change 12.45% 9.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.805M $3.441M
YoY Change 41.03% 14.43%
Accrued Expenses $8.164M $8.956M
YoY Change 42.5% 44.54%
Deferred Revenue
YoY Change
Short-Term Debt $3.670M $0.00
YoY Change -50.75% -100.0%
Long-Term Debt Due $25.21M $30.47M
YoY Change 26.17% 48.94%
Total Short-Term Liabilities $60.92M $61.55M
YoY Change 46.71% 33.58%
LONG-TERM LIABILITIES
Long-Term Debt $3.560M $3.416M
YoY Change 5.29%
Other Long-Term Liabilities $17.24M $18.13M
YoY Change -46.33% -42.79%
Total Long-Term Liabilities $17.24M $18.13M
YoY Change -46.33% -42.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $60.92M $61.55M
Total Long-Term Liabilities $17.24M $18.13M
Total Liabilities $83.78M $85.32M
YoY Change 5.0% 5.82%
SHAREHOLDERS EQUITY
Retained Earnings -$257.3M -$257.4M
YoY Change 1.89% 2.08%
Common Stock $222.5M $222.5M
YoY Change 0.74% 0.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$36.33M -$35.03M
YoY Change
Total Liabilities & Shareholders Equity $47.45M $50.29M
YoY Change 12.45% 9.35%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $67.00K -$1.482M
YoY Change -117.14% -83.33%
Depreciation, Depletion And Amortization $7.000K $9.000K
YoY Change -22.22% -10.0%
Cash From Operating Activities $60.00K -$1.305M
YoY Change -106.29% 22.77%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $5.000K
YoY Change -131.25%
Acquisitions
YoY Change
Other Investing Activities -$400.0K $1.069M
YoY Change -55.56% -165.34%
Cash From Investing Activities -$400.0K $1.064M
YoY Change -55.56% -164.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 490.0K -153.0K
YoY Change -76.82% -105.29%
NET CHANGE
Cash From Operating Activities 60.00K -1.305M
Cash From Investing Activities -400.0K 1.064M
Cash From Financing Activities 490.0K -153.0K
Net Change In Cash 150.0K -394.0K
YoY Change -42.31% -321.35%
FREE CASH FLOW
Cash From Operating Activities $60.00K -$1.305M
Capital Expenditures $0.00 $5.000K
Free Cash Flow $60.00K -$1.310M
YoY Change -106.29% 25.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000822370
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35527
dei Entity Registrant Name
EntityRegistrantName
EMMAUS LIFE SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0419387
dei Entity Address Address Line1
EntityAddressAddressLine1
21250 Hawthorne Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
dei Entity Address City Or Town
EntityAddressCityOrTown
Torrance
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90503
dei City Area Code
CityAreaCode
310
dei Local Phone Number
LocalPhoneNumber
214-0065
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53637554
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
609000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1361000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2021000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5573000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
375000
CY2023Q2 us-gaap Inventory Net
InventoryNet
1814000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2379000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1099000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1514000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
9847000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
6289000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2023Q2 us-gaap Equity Method Investments
EquityMethodInvestments
18302000
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
18828000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2585000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2799000
CY2023Q2 emma Investment In Convertible Bond
InvestmentInConvertibleBond
19210000
CY2022Q4 emma Investment In Convertible Bond
InvestmentInConvertibleBond
19971000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
276000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2023Q2 us-gaap Assets
Assets
50288000
CY2022Q4 us-gaap Assets
Assets
48225000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15200000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13549000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
775000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
703000
CY2023Q2 emma Conversion Feature Derivative Note Payable
ConversionFeatureDerivativeNotePayable
4217000
CY2022Q4 emma Conversion Feature Derivative Note Payable
ConversionFeatureDerivativeNotePayable
3248000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13994000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12917000
CY2023Q2 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
1111000
CY2022Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
70000
CY2023Q2 emma Notes Payable Current Excluding Convertible Notes Payable Current
NotesPayableCurrentExcludingConvertibleNotesPayableCurrent
8462000
CY2022Q4 emma Notes Payable Current Excluding Convertible Notes Payable Current
NotesPayableCurrentExcludingConvertibleNotesPayableCurrent
6814000
CY2023Q2 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2482000
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2367000
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14306000
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14655000
CY2023Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1000000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
61547000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54323000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2225000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2553000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18132000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21714000
CY2022Q4 emma Long Term Notes Payable Excluding Convertible Long Term Notes Payable
LongTermNotesPayableExcludingConvertibleLongTermNotesPayable
380000
CY2023Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
3416000
CY2022Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
3346000
CY2023Q2 us-gaap Liabilities
Liabilities
85320000
CY2022Q4 us-gaap Liabilities
Liabilities
82316000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53637554
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53637554
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49583501
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49583501
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
54000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
222415000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
220815000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-114000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2619000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257387000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252337000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-35032000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-34091000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50288000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48225000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10759000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4287000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17512000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7521000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
508000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
396000
us-gaap Cost Of Revenue
CostOfRevenue
937000
us-gaap Cost Of Revenue
CostOfRevenue
1403000
CY2023Q2 us-gaap Gross Profit
GrossProfit
10251000
CY2022Q2 us-gaap Gross Profit
GrossProfit
3891000
us-gaap Gross Profit
GrossProfit
16575000
us-gaap Gross Profit
GrossProfit
6118000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
320000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
298000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
764000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2531000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1952000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4848000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3412000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4074000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3081000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8957000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6450000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
6925000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
5331000
us-gaap Operating Expenses
OperatingExpenses
14414000
us-gaap Operating Expenses
OperatingExpenses
10626000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3326000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1440000
us-gaap Operating Income Loss
OperatingIncomeLoss
2161000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4508000
CY2023Q2 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
459000
CY2022Q2 emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
542000
emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
445000
emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
1290000
CY2023Q2 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-1058000
CY2022Q2 emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-3695000
emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-969000
emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-615000
CY2023Q2 emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
-297000
emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
-297000
emma Gain Loss On Investment In Convertible Bond
GainLossOnInvestmentInConvertibleBond
-133000
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-439000
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-493000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-966000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1059000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1887000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2470000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2406000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3661000
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
173000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
133000
us-gaap Interest And Other Income
InterestAndOtherIncome
333000
us-gaap Interest And Other Income
InterestAndOtherIncome
355000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1793000
CY2022Q2 us-gaap Interest Expense
InterestExpense
1287000
us-gaap Interest Expense
InterestExpense
3295000
us-gaap Interest Expense
InterestExpense
2024000
CY2023Q2 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-4842000
CY2022Q2 emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-7270000
emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-7155000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
334000
emma Nonoperating Income Expense Including Income Loss From Equity Method Investments
NonoperatingIncomeExpenseIncludingIncomeLossFromEquityMethodInvestments
-5847000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1516000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8710000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4994000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10355000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
182000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
79000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1482000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8892000
us-gaap Net Income Loss
NetIncomeLoss
-5009000
us-gaap Net Income Loss
NetIncomeLoss
-10434000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1909000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4415000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1365000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4065000
CY2023Q2 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
403000
emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
403000
emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
7000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
551000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
643000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
737000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
974000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2863000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3772000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2505000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3084000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1381000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12664000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2504000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13518000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52865353
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52865353
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49319995
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49319995
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51793445
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51793445
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49315952
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49315952
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-34091000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
500000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
37000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-544000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
186000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3527000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-37439000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1909000
CY2023Q2 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
403000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
551000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1482000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-35032000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-21450000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
350000
CY2022Q1 emma Other Comprehensive Income Loss Reclassification Adjustment For Loss Included In Net Income Loss
OtherComprehensiveIncomeLossReclassificationAdjustmentForLossIncludedInNetIncomeLoss
7000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
331000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1542000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-22299000
CY2022Q2 emma Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity
213000
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
110000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4415000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
643000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8892000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-34635000
us-gaap Profit Loss
ProfitLoss
-5009000
us-gaap Profit Loss
ProfitLoss
-10434000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28000
emma Inventory Reserve
InventoryReserve
-16000
emma Inventory Reserve
InventoryReserve
-1008000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1266000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
770000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2382000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-3811000
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
-297000
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
-133000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-966000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1059000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
emma Gain Loss On Sale Of Loss On Leased Assets
GainLossOnSaleOfLossOnLeasedAssets
-22000
us-gaap Share Based Compensation
ShareBasedCompensation
1215000
us-gaap Share Based Compensation
ShareBasedCompensation
10000
emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
445000
emma Gain Loss On Warrant Derivative Liabilities
GainLossOnWarrantDerivativeLiabilities
1290000
emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-969000
emma Gain Loss On Conversion Feature Derivative Note Payable
GainLossOnConversionFeatureDerivativeNotePayable
-615000
emma Gain Loss On Option Instrument
GainLossOnOptionInstrument
7000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5204000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
188000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-543000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-233000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-331000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-365000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-282000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-321000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2201000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1172000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-316000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-3002000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2436000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-431000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2597000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5796000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2232000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2919000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
emma Loan To Equity Method Investee
LoanToEquityMethodInvestee
-2248000
emma Loan To Equity Method Investee
LoanToEquityMethodInvestee
-3326000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-425000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2453000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2918000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
227000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2121000
emma Proceeds From Related Party Convertible Debt
ProceedsFromRelatedPartyConvertibleDebt
1000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1642000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
90000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
50000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1988000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4949000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-24000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-25000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-660000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1297000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2021000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2279000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1361000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
982000
us-gaap Interest Paid Net
InterestPaidNet
1018000
us-gaap Interest Paid Net
InterestPaidNet
285000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-68000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
16000
emma Renewal Of Notes Payable Including Interests Capitalized
RenewalOfNotesPayableIncludingInterestsCapitalized
618000
emma Conversion Of Convertible Note Payable To Common Stock
ConversionOfConvertibleNotePayableToCommonStock
1500000
us-gaap Net Income Loss
NetIncomeLoss
-5000000.0
CY2023Q2 emma Working Capital Deficit
WorkingCapitalDeficit
51700000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
447000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
69300024
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
52523286
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10759000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4287000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17512000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7521000
CY2022Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5491000
emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
3570000
emma Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales
RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales
77000
emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
3359000
CY2023Q2 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5625000
CY2021Q4 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5154000
emma Revenue Allowance And Accrual Activities Provision Related To Sales In Current Year
RevenueAllowanceAndAccrualActivitiesProvisionRelatedToSalesInCurrentYear
2799000
emma Revenue Allowance And Accrual Activities Adjustments Related To Prior Period Sales
RevenueAllowanceAndAccrualActivitiesAdjustmentsRelatedToPriorPeriodSales
-685000
emma Revenue Allowance And Accrual Activities Credit And Payments Made
RevenueAllowanceAndAccrualActivitiesCreditAndPaymentsMade
3197000
CY2022Q2 emma Revenue Allowance And Accrual Activities
RevenueAllowanceAndAccrualActivities
5441000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
430000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2023Q2 us-gaap Depreciation
Depreciation
9000
CY2023Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1362000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1393000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
224000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
513000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5198000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5428000
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4970000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4955000
CY2023Q2 us-gaap Inventory Net
InventoryNet
1814000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2379000
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
328000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
598000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
337000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
467000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
434000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
449000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1099000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1514000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
515000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
505000
CY2022Q2 us-gaap Depreciation
Depreciation
10000
us-gaap Depreciation
Depreciation
18000
us-gaap Depreciation
Depreciation
21000
CY2020Q3 us-gaap Debt Instrument Call Date Earliest
DebtInstrumentCallDateEarliest
2020-09-28
CY2022Q1 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-126000
CY2022Q1 us-gaap Other Income
OtherIncome
41000
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-106000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
19971000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
26100000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
-2232000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
-2919000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
106000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-126000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
1365000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss
-3084000
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
19210000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
19971000
CY2023Q2 emma Clinical And Regulatory Expenses
ClinicalAndRegulatoryExpenses
499000
CY2022Q4 emma Clinical And Regulatory Expenses
ClinicalAndRegulatoryExpenses
361000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
618000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
626000
CY2023Q2 emma Accrued Selling Expenses
AccruedSellingExpenses
1210000
CY2022Q4 emma Accrued Selling Expenses
AccruedSellingExpenses
1363000
CY2023Q2 emma Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
364000
CY2022Q4 emma Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
650000
CY2023Q2 emma Accrued Non Employee Director Compensation
AccruedNonEmployeeDirectorCompensation
620000
CY2022Q4 emma Accrued Non Employee Director Compensation
AccruedNonEmployeeDirectorCompensation
484000
CY2023Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
130000
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
301000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3441000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3785000
CY2023Q2 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
525000
CY2022Q4 emma Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
144000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
2278000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2381000
CY2023Q2 emma Accrued Payroll Salary And Taxes Current
AccruedPayrollSalaryAndTaxesCurrent
1868000
CY2022Q4 emma Accrued Payroll Salary And Taxes Current
AccruedPayrollSalaryAndTaxesCurrent
1263000
CY2023Q2 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
5341000
CY2022Q4 emma Accrued Government Rebates And Other Rebates Current
AccruedGovernmentRebatesAndOtherRebatesCurrent
5536000
CY2023Q2 emma Accured Due To Customer Current
AccuredDueToCustomerCurrent
844000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
903000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
440000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8956000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7239000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15200000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
13549000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13994000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12917000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18132000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21714000
CY2023Q2 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
31323000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
1711000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
29666000
us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
51387647
CY2022Q4 emma Debt Instrument Principal Outstanding Amount
DebtInstrumentPrincipalOutstandingAmount
30418000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
2918000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
27562000
CY2022 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
41644749
CY2023Q2 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.10
CY2022Q4 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.08
CY2023Q2 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.21
CY2022Q4 emma Debt Weighted Average Effective Interest Rate
DebtWeightedAverageEffectiveInterestRate
0.20
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
25499000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2303000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1200000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2321000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
31323000
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
32000
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
84000
emma Warrants Granted Term
WarrantsGrantedTerm
P5Y
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
500000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.50
CY2023Q2 emma Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
18000
emma Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
4000
CY2023Q1 emma Warrants Granted Term
WarrantsGrantedTerm
P5Y
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7500000
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.50
us-gaap Share Based Compensation
ShareBasedCompensation
1200000
emma Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
441000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y3M18D
CY2023Q2 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-34000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
15000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
182000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
79000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
307000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
294000
us-gaap Operating Lease Expense
OperatingLeaseExpense
587000
us-gaap Operating Lease Expense
OperatingLeaseExpense
597000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
542000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1101000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1132000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
846000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3621000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
621000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3000000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2600000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3000000.0
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.129

Files In Submission

Name View Source Status
emma-20230630_cal.xml Edgar Link unprocessable
0000950170-23-042300-index-headers.html Edgar Link pending
0000950170-23-042300-index.html Edgar Link pending
0000950170-23-042300.txt Edgar Link pending
0000950170-23-042300-xbrl.zip Edgar Link pending
emma-20230630.htm Edgar Link pending
emma-20230630.xsd Edgar Link pending
emma-ex10_1.htm Edgar Link pending
emma-ex10_2.htm Edgar Link pending
emma-ex10_3.htm Edgar Link pending
emma-ex10_4.htm Edgar Link pending
emma-ex31_1.htm Edgar Link pending
emma-ex31_2.htm Edgar Link pending
emma-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img110260969_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
emma-20230630_def.xml Edgar Link unprocessable
emma-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
emma-20230630_pre.xml Edgar Link unprocessable
emma-20230630_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending